Table 2a.
Unweighted means for baseline and time-varying confounders for each treatment group between 0 and 3 months and between 3 and 6 months relative to the population mean and standard deviation (SD).
| Treatment Group Between 0 and 3 Months |
|||||
|---|---|---|---|---|---|
| Residential (N=798) | Outpatient (N=1560) | BDS only (N=356) | No Treatment (N=156) | Population Mean (SD) | |
| Female | 0.25 | 0.23 | 0.19 | 0.27 | 0.24 (0.42) |
| Race/ethnicity | |||||
| White | 0.48 | 0.66 | 0.41* | 0.53 | 0.57 (0.50) |
| Black | 0.17 | 0.15 | 0.26* | 0.17 | 0.17 (0.38) |
| Hispanic | 0.17 | 0.10 | 0.19 | 0.14 | 0.13 (0.34) |
| Other | 0.18 | 0.09 | 0.15 | 0.16 | 0.13 (0.33) |
| Age | 16.13 | 15.86 | 15.91 | 16.47* | 15.97 (1.35) |
| Baseline SFS | 0.28* | 0.14* | 0.16 | 0.11* | 0.18 (0.18) |
| Baseline SPSm | 5.54* | 3.23 | 2.98 | 2.76* | 3.81 (4.23) |
| Baseline SPSy | 10.65* | 7.32 | 7.33 | 5.92* | 8.17 (4.66) |
| Baseline EPS | 0.32* | 0.24 | 0.25 | 0.22 | 0.26 (0.21) |
| Baseline days in controlled environment | 20.77* | 8.54* | 18.26 | 23.34* | 13.95 (24.59) |
| Mean dosagea of treatment (interquartile range) | 45 (29, 65) | 13 (5, 16) | 7 (2, 8) | NA | NA |
| Treatment Group Between 3 and 6 Months |
|||||
|---|---|---|---|---|---|
| Residential (N=382) | Outpatient (N=717) | BDS only (N=909) | No Treatment (N=862) | Population Mean (SD) | |
| Female | 0.21 | 0.28 | 0.20 | 0.25 | 0.24 (0.42) |
| Race/ethnicity | |||||
| White | 0.51 | 0.61 | 0.55 | 0.58 | 0.57 (0.50) |
| Black | 0.21 | 0.12 | 0.18 | 0.19 | 0.17 (0.38) |
| Hispanic | 0.11 | 0.15 | 0.13 | 0.12 | 0.13 (0.34) |
| Other | 0.17 | 0.12 | 0.13 | 0.10 | 0.13 (0.33) |
| Age | 16.07 | 15.96 | 15.89 | 16.04 | 15.97 (1.35) |
| Baseline SFS | 0.24* | 0.19 | 0.16 | 0.16 | 0.18 (0.18) |
| Baseline SPSm | 4.84* | 4.00 | 3.48 | 3.56 | 3.81 (4.23) |
| Baseline SPSy | 9.39* | 8.75 | 7.88 | 7.44 | 8.17 (4.66) |
| Baseline EPS | 0.30 | 0.28 | 0.24 | 0.25 | 0.26 (0.21) |
| Baseline days in controlled environment | 16.88 | 13.45 | 14.92 | 12.03 | 13.95 (24.59) |
| SFS at 3 months | 0.08 | 0.06 | 0.08 | 0.08 | 0.07 (0.11) |
| SPSm at 3 months | 2.39 | 2.19 | 2.22 | 2.27 | 2.25 (3.36) |
| EPS at 3 months | 0.29* | 0.24 | 0.19 | 0.20 | 0.22 (0.19) |
| Days ctrl. envir. at 3 months | 48.45* | 17.12 | 16.60 | 11.29* | 19.37 (29.07) |
| Treatment group at 3 months | |||||
| No treatment | 0.02 | 0.03 | 0.05 | 0.10 | 0.05 (0.23) |
| BDS only | 0.07 | 0.08 | 0.18 | 0.12 | 0.12 (0.33) |
| Outpatient | 0.31* | 0.57 | 0.56 | 0.61 | 0.54 (0.50) |
| Residential | 0.60* | 0.32 | 0.21 | 0.17* | 0.28 (0.45) |
| Mean dosagea of treatment (interquartile range) | 54 (23, 90) | 14 (5, 18) | 7 (1, 8) | NA | NA |
*
Denote if PSB comparing the group in question to the population was greater than 0.20.
a
Dosage of treatment is measured in days for residential treatment and number of times for outpatient and BDS.